Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT03989115 trial: what clinicians have said so far
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
- NCT03989115 ↗
- Completed
- Revolution Medicines, Inc.
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT03989115 (RMC-4630 plus cobimetinib; RMC-4630 plus osimertinib in relapsed/refractory solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03989115 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Ph1b/2 Open-Label,Multicenter Dose-Esc & Dose-Exp Study of Combo RMC4630 & Cobimetinib in Participants w/Relapsed/Refractory Solid Tumors & Ph1b Study of RMC4630 w/Osimertinib in Participants w/EGFR Mutation+,Locally Adv or Meta NSCLC
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Solid Tumor
- Interventions
- RMC-4630; Cobimetinib; Drug: Osimertinib
- Arms
- RMC-4630 and Cobimetinib · Experimental
- RMC-4630 and Osimertinib · Experimental
- Enrollment
- 113
- Primary outcomes
- Number of Participants With Adverse Events (AEs).
- Number of Participants With Dose Limiting Toxicities (DLTs)
- Sponsor
- Revolution Medicines, Inc. with Sanofi
- Start
- Jul 2, 2019
- Primary completion
- Feb 8, 2022
- Results posted
- Yes
- Registry record
- NCT03989115 · updated Jun 26, 2023